Expanding Treatment in The Neoadjuvant Setting


Immunotherapy in the neoadjuvant setting shows promise for patients with stage III lung cancer.

Neoadjuvant chemotherapy is the standard treatment for patients with stage III lung cancer, but new studies show promise for the combination of neoadjuvant immunotherapy in these patients, before surgery.

At the 14th Annual New York Lung Cancers Symposium OncLive®, a sister publication to Oncology Nursing News®, had the chance to speak with Ashish Saxena, MD, PhD, medical oncologist at Weil Cornell Medicine, on this new avenue for treatment and what the standard treatment is for patients with stage III lung cancer.


Generally, for patients with stage III disease, we typically do neoadjuvant chemotherapy as a standard treatment. Trials are going on, including one that we are doing at our institution of neoadjuvant immunotherapy to get a similar response in the tumor before surgery, and then to see if that translates into better overall survival for the patient. Generally, we decide treatment based on the stages and for stage three we typically do neoadjuvant therapy.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.